“During the second quarter, both of our lead programs generated clinical data that further strengthened their competitive positioning. BI-1808 (anti-TNFR2) reported new results in two distinct indications, recurrent ovarian cancer and cutaneous T-cell lymphoma (CTCL), each a setting where patients have few effective options after standard treatment fails. BI-1206 (anti-FcγRIIB) reported triplet combination data in relapsed/refractory non-Hodgkin’s lymphoma (NHL) that compares favorably with recently approved regimens. We presented these results at ASCO and EHA and discussed them directly with the clinical community through two KOL events.” - Martin Welschof, CEO of BioInvent.

EVENTS IN THE SECOND QUARTER

• BioInvent revealed solid data for the BI-1808 and KEYTRUDA® (pembrolizumab) combination (ASCO 2026):
  24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA — multiplying by three the historical KEYTRUDA single agent activity of 8% in KEYNOTE-100 (2019) (R)
• BI-1808 showcased strong activity and immune activation data as single agent and in combination with KEYTRUDA in advanced CTCL (EHA 2026)
• BI-1206 triplet combination with rituximab and acalabrutinib achieved 83% response rate in refractory NHL with improved safety vs. standard of care (EHA 2026)
• Two successful KOL events showcasing the positive ASCO and EHA data for BI-1808 and BI-1206

EVENTS AFTER THE END OF THE PERIOD

• BI-1808 received FDA Fast Track Designation for the treatment of ovarian cancer
• BioInvent’s BI-1808 abstract from Modest to Meaningful in platinum-resistant ovarian cancer accepted for poster presentation at ESMO 2026
• BioInvent published two scientific papers in peer-reviewed journals. One in Cancer Research: “Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Employ Distinct Modes of Action to Induce Antitumor Immunity” and one in JECCR: Tailored FcγR Blockade with BI-1206 and BI-1607 Enhances Cancer Antibody Therapies and Overcomes Resistance in Preclinical Models

(R)= Regulatory event

FINANCIAL INFORMATION
Second quarter 2026

• Net sales SEK 12.8 (198.1) million.
• Profit/loss after tax SEK -122.9 (38.8) million.
• Profit/loss after tax per share before and after dilution SEK -1.87 (0.59)
• Cash flow from operating activities SEK -112.0 (66.8) million.

January – June 2026

• Net sales SEK 26.2 (220.2) million.
• Profit/loss after tax SEK -242.1 (-77.8) million.
• Profit/loss after tax per share before and after dilution SEK -3.68 (-1.18)
• Cash flow from operating activities SEK -244.8 (-53.2) million.
• Liquid funds and current investments as of June 30, 2026: SEK 340.8 (797.5) million.

The complete interim report is available for download below and on the company’s website under Financial reports.

About BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with drug candidates in ongoing clinical programs in Phase 1/2 trials for the treatment of solid tumors and hematological cancer. The Company's validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities.

The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com.

For further information, please contact:
Cecilia Hofvander, VP Investor Relations
Phone: +46 (0)46 286 85 50
Email: cecilia.hofvander@bioinvent.com

BioInvent International AB (publ)
Co. Reg. No.: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com